SOT 2021 Recap: Spotlight on Dose-Response and the MDCPSS Best Overall Abstract Award Winner 🏅

SenzaGen had a busy program at SOT 2021. To highlight our expanding capabilities in in vitro skin toxicology, we took part in several activities and presented our novel assays for quantitative skin sensitizing potency assessment and medical device testing.


Exhibitor Hosted Session: Dose-response for predicting skin sensitization potency

Listen to SenzaGen’s Chief Scientist Dr Henrik Johansson presenting the latest development on GARD™skin Dose-Response, our novel in vitro assay for quantitative skin sensitizing potency assessment:


Workshop: Applicability domains and future of non-animal tests for skin sensitization

Learn from Dr Andy Forreryd how GARD™ and other in vitro assays can be used to fill data gaps in sensitizing hazard and potency assessment of chemicals:


Posters by SenzaGen and jointly with Corteva

Quantitative Sensitizing Potency Assessment Using GARD™skin Dose-Response| Request a copy

GARD™skin and GARD™potency: A Proof-of-Concept Study to Investigate the Applicability Domain for Agrochemical Formulations| View abstract

🏅 MDCPSS Best Overall Abstract Award Winner🏅

Applicability Domain of the GARD™skin Medical Device Test for In Vitro Skin Sensitization Testing of Medical Devices| Request a copy


Dr Rose-Marie Jenvert, one of the authors of the winning poster abstract